News & Events

In this section

Instem Expands SEND Suite with Data Visualization and Analysis Solution

Instem Signs Agreement with Integrated Nonclinical Development Solutions, Inc.; Becomes Exclusive Global Supplier of SEND Explorer®

CONSHOHOCKEN, PA - (BUSINESS WIRE) – July 29, 2016 - -Instem, a leading provider of IT solutions to the global early development healthcare market, announced today that it has reached an agreement with Integrated Nonclinical Development Solutions, Inc. (“INDS”) to market, sell and support its SEND Explorer solution worldwide.

SEND Explorer provides advanced single and multi-study viewing, data summarization, and visualization capabilities for study data produced in SEND (Standard for Exchange of Nonclinical Data) format.  SEND Explorer is an intuitive web-based application with optional data warehousing capabilities allowing data sources other than SEND to be integrated and available for querying and analysis.  

“SEND Explorer is the perfect complement to Instem’s current SEND offerings,” comments Jennifer Feldmann, Vice President of SEND Product Strategy at Instem.  “Our clients can create and manage their SEND datasets using submit™, QC the datasets with SENDView™ to ensure a submission-ready package, and use those SEND datasets with SEND Explorer as part of the ongoing analysis to support the scientific findings submitted with a drug application.”

Instem views SEND Explorer as an effective solution for organizations to further leverage their investment in SEND data. The SEND Explorer solution, an INDS technology, will become an integral part of Instem’s submit solution suite.

“INDS designed SEND Explorer to help scientists efficiently visualize and communicate data patterns and trends within and across studies, thereby accelerating the drug evaluation process,” states Joyce Zandee, Chief Operating Officer at INDS. “As the global SEND market leader, Instem has both the expertise and resources to make SEND Explorer accessible to scientists at large and small organizations, allowing our industry to greatly benefit from the data standardization imposed by SEND.”

Instem developed submit, the first commercially available SEND software solution in 2005 and its comprehensive set of tools are now the most widely adopted in the market, supporting over 45 client sites across 15 countries. The submit platform is meeting the very wide range of demands that span the needs of the largest multi-national pharmaceutical organizations and CROs to the smallest organizations and their advisors.

During this period of preparation and especially following FDA’s long awaited final guidance (December 18, 2014) for standardized study data for providing submissions in electronic format, the demand for outsourced SEND services has rapidly grown. Now across every stage of SEND-Readiness, clients can choose from one or more Instem solution-services that will help them in their journey towards SEND compliance, while minimizing the impact within their organization. This includes the option for organizations to completely turn to Instem as their fully-outsourced SEND department.

More information about how organizations can Submit with Confidence™ can be found here.

About Instem

Instem is a leading supplier of IT applications and services to the early development healthcare market delivering compelling solutions for data collection, analysis and regulatory submissions management. Instem solutions are in use by customers worldwide, meeting the rapidly expanding needs of life science and healthcare organizations for data-driven decision making leading to safer, more effective products.

Instem’s portfolio of software solutions and consulting services increases client productivity by enhancing product development processes while offering the unique ability to generate new knowledge through the extraction and harmonization of actionable scientific information.

Instem supports over 500 clients through offices in the United States, United Kingdom, Japan, China and India.

Press Contacts:

Gary Mitchell (US HQ) 
Tel: 610-941-0990

Julie Jones (UK HQ) 
Tel: +44 (0) 1785 825600